Lixte Biotechnology Holdings Inc LIXT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LIXT is a good fit for your portfolio.
News
-
LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial
-
LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial
-
Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System
-
LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer
-
LIXTE Biotechnology Holdings Provides Update on Recent Activities
-
LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”
-
Lixte Bio Shares Jump on LB-100 Trial
Trading Information
- Previous Close Price
- $2.40
- Day Range
- $2.28–2.45
- 52-Week Range
- $1.58–4.73
- Bid/Ask
- $2.10 / $2.33
- Market Cap
- $5.22 Mil
- Volume/Avg
- 9,068 / 34,229
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 4
- Website
- https://www.lixte.com
Valuation
|
Metric
|
LIXT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LIXT
|
|---|---|
Quick Ratio | 7.38 |
Current Ratio | 7.75 |
Interest Coverage | −239.62 |
Quick Ratio
LIXT
Profitability
|
Metric
|
LIXT
|
|---|---|
Return on Assets (Normalized) | −99.51% |
Return on Equity (Normalized) | −1,552.82% |
Return on Invested Capital (Normalized) | −108.60% |
Return on Assets
LIXT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Sfkfgbglbf | Slhfk | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Wdnyhbvxv | Hhbjl | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Xgzjzyd | Lhbxkrr | $118.7 Bil | |||
| Moderna Inc
MRNA
| Jpqphhyyj | Qyvx | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Yvcgxcmps | Dtvctz | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Pppszkfx | Mbh | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Qbzmjnkwt | Nfjc | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Vmvzgfxv | Vsrqsv | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Ltbmvnkk | Wlcgz | $15.0 Bil | |||
| Incyte Corp
INCY
| Synyxdcm | Brzzkg | $13.5 Bil |